Entera Bio (ENTX) Total Non-Current Liabilities (2017 - 2026)
Entera Bio's (ENTX) quarterly Total Non-Current Liabilities came in at $866000.0 in Q1 2026, up 44.82% YoY from $598000.0 in Q1 2025, and up 25.69% on a QoQ basis from $689000.0 in Q4 2025.
Entera Bio (ENTX) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has 10 years of Total Non-Current Liabilities data on file, last reported at $866000.0 in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 44.82% year-over-year to $866000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $866000.0 (up 44.82% YoY) and the FY2025 annual result came in at $689000.0, up 414.18% from the prior year.
- Total Non-Current Liabilities grew to $866000.0 in Q1 2026, from $689000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $866000.0 in Q1 2026 to a low of $32000.0 in Q4 2022.
- A 5-year average of $323235.3 and a median of $255000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 87.74% — and 2023, when it surged 800.0%.
- Tracing ENTX's Total Non-Current Liabilities over 5 years: stood at $32000.0 in 2022, then surged by 800.0% to $288000.0 in 2023, then tumbled by 53.47% to $134000.0 in 2024, then surged by 414.18% to $689000.0 in 2025, then rose by 25.69% to $866000.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at $866000.0 (Q1 2026), $689000.0 (Q4 2025), and $602000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | 10.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.11 Mn |
| Mar 31, 2026 | 866,000.00 |
| Dec 31, 2025 | 689,000.00 |
| Sep 30, 2025 | 602,000.00 |
| Jun 30, 2025 | 567,000.00 |
| Mar 31, 2025 | 598,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Sep 30, 2024 | 178,000.00 |
| Jun 30, 2024 | 209,000.00 |
| Mar 31, 2024 | 255,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Sep 30, 2023 | 302,000.00 |
| Jun 30, 2023 | 348,000.00 |
| Mar 31, 2023 | 32,000.00 |
| Dec 31, 2022 | 32,000.00 |
| Sep 30, 2022 | 35,000.00 |
| Jun 30, 2022 | 127,000.00 |
| Mar 31, 2022 | 233,000.00 |
| Dec 31, 2021 | 261,000.00 |
| Jun 30, 2021 | 275,000.00 |